Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.
The US Food and Drug Administration has approved foscarbidopa and foslevodopa , a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for the treatment of motor fluctuations in adults with advanced Parkinson ’s disease .
Due to the progressive nature of PD, “oral medications are eventually no longer as effective at motor symptom control and surgical treatment may be required. This new, non-surgical regimen provides continuous delivery of levodopa morning, day, and night,” Robert A. Hauser, MD, MBA, director of the Parkinson's and Movement Disorder Center at the University of South Florida, Tampa, said in a news release. showed that patients treated with foscarbidopa/foslevodopa had superior improvement in motor fluctuations, with increased"on" time without troublesome dyskinesia and decreased"off" time, compared with peers receiving oral immediate-release carbidopa/levodopa. At week 12, the increase in"on" time without troublesome dyskinesia was 2.72 hours for foscarbidopa/foslevodopa continuous infusion versus 0.97 hours for carbidopa/levodopa ( Improvements in"on" time were observed as early as the first week and persisted throughout the 12 weeks.Most adverse reactions with foscarbidopa/foslevodopa were non-serious and mild or moderate in severity. The most frequent adverse reactions were infusion site events, hallucinations, and dyskinesia.
Parkinson Disease Parkinsons Parkinson Parkinson Disease (PD) L-Dopa Levodopa Dyskinesia Florida U.S. Food And Drug Administration United States Food And Drug Administration Fda Hallucination Medicare Movement Disorder
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast CancerUnlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
Read more »
FDA OKs First Treatment for Rare, Deadly Genetic DisorderMiplyffa treats Niemann-Pick disease type C, which progressively impacts the abilities to speak, swallow, and walk or move independently.
Read more »
FDA OKs First-in-Class Antipsychotic for SchizophreniaThe FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
Read more »
FDA Approves Cobenfy, First Novel Schizophrenia Drug in DecadesThe FDA has approved Cobenfy (cobrenify), a new twice-daily pill developed by Bristol Myers Squibb, as the first novel treatment option for schizophrenia in over 70 years. The medication is expected to be available in late October with a monthly cost of $1,850.
Read more »
FDA OKs Next-Gen Cologuard Test for CRC ScreeningIn average-risk adults, Cologuard Plus demonstrated sensitivities of 95% for CRC and 43% for advanced precancerous lesions at 94% specificity in the pivotal BLUE-C trial.
Read more »
FDA OKs Once-Nightly Lumryz for Children With NarcolepsyLumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children as young as 7 years with narcolepsy.
Read more »